Professional Documents
Culture Documents
370 to 420 nm
LIOLs
Eyeonics: Crystalens
Alcon: AcrySof AMO: TECNIS, ReZoom, ClariFlex, Sensar B&L: SofPort AO, Violet Shield AO
None
Alcon: AcrySof Natural, AcrySof ReSTOR, AcrySof IQ
Porque no Bloqearla?
La Luz Azul -probado ser esencial para una Vision Optima Escotopico y el Ritmo Circadio Saludable1-4
1. Mainster. BJO. 2006. 2. Lehrl. JNT. 2006. 3. Cajochen. EJN. 2006. 4. Mirjam-Munch. AJP. 2006.
14-
21-
La Vision Escotopico disminuye con la edad, aun en ojos saludables sin cataratas o problemas de retina. 2 porque reducirla mas?
Adaptacion a la Obscuridad se dificulta, aumenta el riesgo de una caida , hospitalizacion y muerte en adultos mayores. (40% > 65 aos sufren caidas cada ao. ) Dificultades en manejar de noche con personas de tercera edad. *
Melotinina es el factor clave controlando el ritmo natural de circadio * Produccin y supresin de Melatonina afecta el sueno, animo, memoria y salud sistmico * Supresion de Melatonina es controlado por la celulas ganglionas sensitivas a la luz azul La Luz Azul da 55% a la supresin de melotonina. *
*Mainster. BJO. 2006
Melatonin Increased
LIOL Con Bloqueadores de la Luz Azul disminuyen la supresin de Melatonina por 27 0 38%* 0
-5 -10 -15 -20 -25 -30 -35 -40
AcrySof Natural 30D
* Mainster. BJO. 2006.
27-
Taylor HR, West S, Munoz B, Rosenthal FS, Bressler SB, Bressler NM. The long-term effects of visible light on the eye [840]. Arch Ophthalmol 1992;110:99-104. Cruickshanks KJ, Klein R, Klein BE, et al. Sunlight and the 5year incidence of early age-related maculopathy [4900]. Arch Ophthalmol 2001;119:246-50. Hirvela H, Luukinen H, Laara E, Sc L, Laatikainen L. [500] Risk factors of agerelated maculopathy in a population 70 years of age or older. Ophthalmology 1996;103:871-7 Delcourt C, Carriere I, Ponton-Sanchez A, Fourrey S, Lacroux A, Papoz L. Light exposure and the risk of age-related macular degeneration: the Pathologies Oculaires Liees a l'Age (POLA) study [2600]. Arch Ophthalmol 2001;119:1463-8. McCarty CA, Mukesh BN, Taylor HR, et al. Risk factors for age-related maculopathy: Visual Impairment ProjectRisk [4700]. Arch Ophthalmol The Eye Diseasethe Case-Control Study Group. factors for neovascular age2001;119:1455-62. related macular degeneration [421]. Arch Ophthalmol 1992;110:1701-8. AREDS P, Report No.P, 19. Risk factors for the incidence of advanced ARMD in the Darzins Mitchell Heller RF. Sun exposure and age-related macular Age-Related Eye Disease Studycase-control (AREDS). Ophthalmol 112:533-39. degeneration. An Australian study [409].2005; Ophthalmology 1997;104:770-6. Khan JC, Shahid H, Bird AC. Age-related macular degeneration and sun
Resumen
1. Tratamiento de catarata es una oportunidad de una vez en la vida, para optimizar el rendimiento visual, salud y mejorar el estilo de vida para adultos mayores.
2. Niveles de Luz Azul que recibe el ojo joven son esenciales para optima vision escotopico y mantener el ritmo circadio saludable. 3. No hay estudios clinicos o experimentales que muestran que la luz azul causa AMD.
References
Asplund R, Eidervik, Linblad B. The development of sleep in persons undergoing cataract surgery. Arch Gerontol Geriatr. 2002 Sep-Oct;35(2):17987. Asplund R, Lindblad BE. Sleep and sleepiness 1 and 9 months after cataract surgery. Arch Gerontol Geriatr 2004; 38:69-75. Cajochen C., Jud C., Munch M., Evening exposure to blue light stimulates the expression of the clock gene PER2 in humans. European Journal of Neuroscience. 2006:PP-1-5 Charman WN. Age, lens transmittance and the possible effects of light on melatonin suppression. Ophthalmology Physiology Opt. 2003:23: No2 Jackson GR. Pilot study on the effect of a blue-blocking IOL on rod-mediated (scotopic) vision. ASCRS Symposium on Cataract, IOL and Refractive Surgery, Washington, DC, 2005 Lehrl S., Gerstmeyer J., Jacob H., Blue Light Improves Cognitive Performance. Journal of Neural Transmission. Published online January 2007 Mainster A, The Spectra, Classification, and Rationale of Ultraviolet-Protective Intraocular Lenses. American Journal of Ophthalmology. 1986:102;727-732
Mainster A, Violet and blue light blocking intraocular lenses: photoprotection vs. photoreception. Br J Ophthalmol 2006: 90; 784-792
References
Munch M., Kobialka S., Steiner R., Wavelength-dependent effects of evening light exposure on sleep architecture and sleep EEG power density in men. American Journal of Physiology. 2006: 290;1421-1428 Scilley K, Jackson G, Cideciyan A, et al. Early Age-related Maculopathy and Self-reported Visual Difficulty in Daily Life. Ophthalmology. 2002; 109(7):123542. Thapan K, Aredt J, Skene DJ, . An Action Spectrum for Melatonin Suppression: Evidence For A Novel Non-Rod, Non-Cone Photorecpetor System In Humans. J Physiol 2001; 535:261-7 Werner J S. Night vision in the elderly: consequences for seeing through a blue filtering intraocular lens. Br J Ophthalmol 2005;89:15181521. Schwiegerling J. Blue-light-absorbing lenses and their effect on scotopic vision. JCRS 2006;32:141-144.
TECNIS, ReZoom, ClariFlex and Sensar are trademarks of Advanced Medical Optics, Inc. AcrySof and ReSTOR are trademarks of Alcon, Inc. Crystalens is a trademark of eyeonics, Inc. Sofport and VioletShield are trademarks of Bausch and Lomb, Inc.